Mendalur

Levosimendan, the active ingredient in Mendalur, is a calcium sensitizer presented as an intravenous formulation for intravenous use. It enhances cardiac contractility and is used in the treatment of acute decompensated heart failure in adult patients.

GNH USA supplies Mendalur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is indicated for conditions involving impaired cardiac function where inotropic support is required.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Chronic severe heart failure (adjunctive): may be used in specialized settings to augment standard therapy. Cardiogenic shock: provides inotropic and vasodilatory support when conventional agents are insufficient.

Levosimendan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypotension: drop in blood pressure, especially after infusion start. - Headache: transient, often related to vasodilation. - Nausea or vomiting: gastrointestinal discomfort. - Flushing: warm sensation and reddening of skin. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Myocardial ischemia: chest pain or ECG changes. - Life‑threatening arrhythmias: ventricular tachycardia or fibrillation. - Tachycardia: rapid heart rate unresponsive to treatment. - Anaphylactic reactions: rare but possible hypersensitivity.

Levosimendan requires careful monitoring and specific safety measures.

Monitor blood pressure: watch for hypotension during and after infusion. Assess cardiac rhythm: continuous ECG monitoring for arrhythmias. Evaluate renal function: adjust use in severe renal impairment. Avoid in severe hypotension: contraindicated when systolic BP <90 mmHg. Use cautiously in the elderly: start at lower infusion rates. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid): - Concurrent strong vasodilators (e.g., nitroglycerin): risk of profound hypotension. - Other calcium sensitizers: additive inotropic effect may cause cardiac stress. - High‑dose beta‑blockers: may blunt therapeutic response.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - ACE inhibitors or ARBs: observe blood pressure closely. - Anticoagulants: watch for bleeding if hypotension occurs.